Expanding Our Scientific Capacity: Welcoming Onat A. to MUB Medical

By Yasar Shaikh in 2025 Posted September 5, 2025

We are pleased to announce that Onat Akbulut, has joined MUB Medical Solutions as part of our growing scientific and technical development team.

Onat is currently pursuing his PhD in Cell & Tissue Engineering and holds a degree in Metallurgical and Materials Engineering. His academic work is anchored in Bioengineering and the Cell & Tissue Engineering, where he focuses on the interface between biological tissues and engineered materials.

At MUB, Onat will play a central role in the design and development of pre-clinical studies related to our Sutrips technology. His expertise in tissue healing, material-tissue interaction, and biological response analysis brings important depth to our product development team. He will also contribute to material evaluation and help ensure that our choices align with both clinical performance goals and biological compatibility standards.

With Onat joining forces with Natale Rolim and Sara Zulfiqar, we are building a dedicated and interdisciplinary foundation for moving Sutrips forward through the final stages of product development, pre-clinical validation, and regulatory preparation.

“With Onat on board, we gain not only deep academic expertise but also a scientific mindset that complements our regulatory and clinical development goals. His contribution will be important as we finalize our pre-clinical planning and ensure the biological strength of our technology,” says Yasar Shaikh, CEO of MUB Medical Solutions.

We look forward to the next steps in our journey and are proud to have Onat as part of the team.

Building the Foundation: Two Key Regulatory Profiles Join MUB Medical Solutions

By Yasar Shaikh in 2025 Posted August 29, 2025

As MUB Medical Solutions continues the development of Sutrips, we are strengthening our team with the core competencies needed to bring the technology through the next critical phases — including material development and validation, regulatory alignment, and clinical readiness.

We are therefore pleased to welcome Dr. Natale Rolim and Sara Zulfiqar to the MUB team. Their expertise will be instrumental in laying the groundwork for the product’s completion and in supporting the regulatory and documentation processes required to prepare Sutrips for future clinical testing and market introduction.

Dr. Natale Rolim – Regulatory Affairs Specialist

With a scientific background and experience in health innovation, Dr. Natale Rolim will lead the development of our regulatory strategy. Her work will focus on aligning Sutrips with both FDA and EUMDR requirements, and ensuring that all processes are structured, compliant, and scalable. Natale’s insight will be central in preparing the product for the demanding documentation and traceability standards required in medical device development.

Sara Zulfiqar – Biomedical Innovation & Quality Systems

With a Master’s in Biomedical Innovation & Development from Georgia Institute of Technology, USA, Sara brings practical experience in building regulatory systems from the ground up. At MUB, she will contribute to:

• Shaping the 510(k) pathway for FDA clearance
• Designing IEC 62366-1 compliant Human Factors Engineering (HFE) studies
• Authoring and implementing a QMS in line with ISO 13485:2016 tailored to Class II medical devices

“The recruitment of Natale and Sara marks an important step in building the internal capacity needed to finalize the development of Sutrips. Their expertise will enable us to qualify materials, strengthen documentation processes, and ensure regulatory readiness for both the EU and US markets. We are still in an active development phase, and these hires represent the foundation we need to complete the work ahead,” says Yasar Shaikh, CEO of MUB Medical Solutions.

At MUB Medical, we remain committed to developing innovative wound closure solutions that are safe, simple, and clinically meaningful — and we are proud to now have Natale and Sara onboard to support that mission.